Undifferentited Carcinomas: What are the issues

Keith M Kerr

Department of Pathology

Aberdeen University Medical School

Aberdeen, UK

Large Cell Carcinoma and Sarcomatoid Carcinomas

2004 WHO Classification	2015 WHO Classification		
Squamous Cell Carcinoma	Adenocarcinoma		
Small Cell Carcinoma	Squamous Cell Carcinoma		
Adenocarcinoma	Neuroendocrine tumours		
Large cell carcinoma	Large Cell Carcinoma		
Adenosquamous carcinoma	Adenosquamous carcinoma		
Sarcomatoid carcinoma	Sarcomatoid carcinomas		
Carcinoid tumour	Other and Unclassified carcinomas		
Salivary gland tumours	Salivary gland tumours		

Undifferentiated carcinomas: Context

- Surgically resected tumours
 - Undifferentiated carcinomas without evidence of severe pleomorphism, tumour giant cells or spindle cells: Large Cell Carcinoma
 - Undifferentiated carcinoma with evidence of severe pleomorphism, tumour giant cells or spindle cells: Sarcomatoid Carcinomas

 This discussion excludes consideration of undifferentiated carcinoma in the context of a small biopsy or cytology samples: NSCLC-NOS. In the majority of these cases, the tumour IS differentiated, only the differentiated components have not been sampled.

Large Cell Carcinoma: 2004 definition

Definition

Large cell carcinoma is an undifferentiated non-small cell carcinoma (NSCC) that lacks the cytological (and architectural) features of small cell carcinoma, adenocarcinoma, or squamous cell carcinoma. The diagnosis requires a thoroughly sampled resected tumour, and cannot be made on non-resection or cytology specimens.




Large Cell Carcinomas: 2004


- Non-variant Large Cell Carcinoma, NOS
- Variant Large Cell Carcinomas
 - Basaloid Carcinomas
 - Large Cell Neuroendocrine Carcinomas
 - Lymphoepithelioma-like Carcinomas
 - Clear Cell Carcinoma
 - Large Cell carcinoma with Rhabdoid phenotype


Large Cell Carcinoma – NOS

- Clinically and radiologically similar to other NSCLCs
- Males, smoking related
- Tend to be more peripheral, large masses, but not always
- Pleural and Chest wall invasion common
- Usual metastatic sites










Tumour progression and de-differentiation




how they call marginal cases

A Genomics-Based Classification of Human Lung Tumors

The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM)

Sci Transl Med. 2013 October 30; 5(209): 209ra153. doi:10.1126/scitranslmed.3006802.



Large Cell Carcinomas - Mutations

N =	Country	EGFR	KRAS	ALK	BRAF	РІКЗСА	MEK
31	Italy	0	0	-	-	-	-
6	Italy	0	50%	-	-	-	-
18	Japan	0	6%	-	-	-	-
72	Scotland	0*	8.3%	0	1	0	-
102	USA	1	29%	3	2	1	1
20	Italy	1	40%	1	-	-	-
57	USA	1	43%	-	-	-	-
verall p	revalence	1%	25%	2%			

Mutations largely matched IHC lineage, where data are available

* EGFR c.2508C>T;p. R836R (SNP) in a Basaloid Ca

Marchetti A et al. J Clin Oncol 2005 Sartori G et al. Am J Clin Pathol 2009 Takeuchi et al, J Clin Oncol 2006 Kerr KM et al, Lung Cancer 2012 Rekhtman N et al. Mon Pathol 2013 Rossi G et al, Virch Arch 2014 Hwang D et al, Arch Path Lab Med 2014

Large Cell Carcinoma: 2015 definition

Definition

Large cell carcinoma is an undifferentiated

non-small cell carcinoma (NSCC)

that lacks the cytological, architectural

and immunohistochemical


features of small cell carcinoma, adenocarcinoma,

or squamous cell carcinoma. The diagnosis

requires a thoroughly sampled resected

tumour, and cannot be made on

non-resection or cytology specimens.





2015: Adenocarcinoma: Solid subtype

NapsinA


CK5/6

TTF1





Undifferentiated carcinoma which is not Small Cell (or LCNEC) IN A RESECTION SPECIMEN




ICD-O code Large cell carcinoma 8012/3

Based on their immunohistochemical profiles, three subtypes of large cell carcinoma can be distinguished

- Large cell carcinoma with **null** immunohistochemical features
- Large cell carcinoma with **unclear** immunohistochemical features
- Large cell carcinoma with **no** additional stains

30% of former cohort remains?

Tumour progression and de-differentiation



how they call marginal cases !!!!


Which markers and how much staining?

For Adenocarcinoma

- TTF1
- Napsin A
- Surfactant apoproteins
- CK7
- Definite staining but it can be weak and patchy
- Which clone?

For Squamous Cell Carcinoma

- P63
- P40
- CK5/6
- Desmocollin
- 34betaE12
- Strong and diffuse staining ONLY



1-7: Sarcomatoid Carcinomas

- 1-7A Pleomorphic, Spindle cell and Giant cell carcinomas
- 1-7B Carcinosarcoma
- 1-7C Pulmonary Blastoma

No change to the definitions or categories. IHC is not a feature of classification.

Pleomorphic, Spindle cell and Giant cell carcinomas

Definition

Pleomorphic carcinoma is a poorly differentiated non-small cell lung carcinoma that contains at least 10% spindle and/or giant cells, with the remainder of the tumour showing squamous cell carcinoma, adenocarcinoma, or undifferentiated non-small cell carcinoma.

Spindle cell carcinoma consists of an almost pure population of epithelial spindle cells, with no differentiated carcinomatous elements.


Giant cell carcinoma consists almost entirely of tumour giant cells (including multinucleated cells), with no differentiated carcinomatous elements.


Sarcomatoid Carcinomas

- Many are combined with 'standard' NSCLC elements
 - Adenocarcinoma
 - Squamous cell carcinoma
 - Large Cell carcinoma
- Pure forms are very rare
 - Giant cell carcinoma
 - Spindle cell carcinoma


1-3% of Lung Cancers








Sarcomatoid carcinoma with squamous cell carcinoma



Sarcomatoid (giant cell) carcinoma



Sarcomatoid (pleomorphic) carcinoma



'Relatively' Pure Spindle Cell and Giant Cell Carcinoma are extremely rare

Sarcomatoid Carcinomas - Mutations

No of Cases	Country	EGFR mutations	KRAS mutations	BRAF/ALK/PIK3CA
61	Korea	15% 89% exon19del 11% L858R exon21	10%	-
17	Japan	18% 67% exon19del 33% L858R exon21	-	-
13	Italy	0	37%	-
27	Italy	-	22%	-
35	Scotland	0	28.6%	0

Lee S et al. J Can Res Clin Oncol 2010 Kaira K et al. J Thorac Oncol 2010 Sartori et al. Am J Clin Pathol 2009 Pelosi G et al. Mod Pathol 2004

Conclusions

- Undifferentiated carcinomas still exist!
- Expression of lineage markers may inform on biology
- Expression of lineage markers may correlate with mutation profile
- Mutation profiles are dominated by KRAS mutations



June 22, 2015

June 26, 2015

July 10, 2015

July 24, 2015

Abstract Notifications

Early Registration Deadline

Regular Registration Deadline

Late Breaking Abstract Submission Deadline

SEPTEMBER 6–10, 2015 → DENVER, COLORADO, USA CURE FOR LUNG CANCER